Novo’s Ozempic copy 15% cheaper, but Discovery still won’t change its position

Source: Business Day — 24 July 2026

Novo Nordisk will launch its lower-cost semaglutide product Extensior in South Africa at a 15% discount from 31 July 2026, but Discovery Health says the cut is still not enough to justify broader medical-scheme funding given the high prevalence of diabetes. The story lands as generic semaglutide approvals accelerate locally.

Read the original article on Business Day